As a first step toward understanding how rare variants contribute to risk for complex diseases, we sequenced 15,585 human protein-coding genes to an average median depth of 111x in 2,440 individuals of European (n=1,351) and African (n=1,088) ancestry. We identified >500,000 single nucleotide variants (SNVs), the majority of which were rare (86% with a minor allele frequency < 0.5%), novel (82%), and population-specific (82%). On average, 2.3% of the 13,595 SNVs each person carries were predicted to impact protein function of ~313 genes per genome, and ~95.7% of SNVs predicted to be functionally important were rare. This excess of rare functional variants is due to the combined effects of explosive, recent accelerated population growth and weak purifying selection. Furthermore, we show that large sample sizes will be required to associate rare variants with complex traits.
Understanding the spectrum of allelic variation in human genes and revealing the demographic and evolutionary forces that shape this variation within and among populations is a major aim of human genetics research. Such information is critical for defining the architecture of common diseases, identifying functionally important variation, and ultimately facilitating the interpretation of personalized disease risk profiles (1) (2) (3) . To date, surveys of human variation have been dominated by studies of single nucleotide polymorphisms (SNPs) genotyped using high-density arrays composed of common variants (4-6). While these projects have substantially improved our knowledge of common allelic variation and enabled genome-wide association studies (GWAS), they have been generally uninformative about the population genetics characteristics of rare variants, defined here as a minor allele frequency (MAF) of less than 0.5%.
Rare genetic variants are predicted to vastly outnumber common variants in the human genome (7, 8) . By capturing and sequencing all protein-coding exons (i.e., the exome, which comprises ~1-2% of the human genome), exome sequencing is a powerful approach for discovering rare variation and has facilitated the genetic dissection of unsolved Mendelian disorders and studying human evolutionary history (9) (10) (11) (12) (13) (14) . Rare and low frequency (MAF between 0.5%-1%) variants have been hypothesized to explain a substantial fraction of the heritability of common, complex diseases (15) . Since common variants explain only a modest fraction of the heritability of most traits (16, 17) , NHLBI recently sponsored the multicenter Exome Sequencing Project (ESP), to identify novel genes and molecular mechanisms underlying complex heart, lung, and blood disorders by sequencing the exomes of a large number of individuals measured for phenotypic traits of substantial public health significance (e.g., earlyonset myocardial infarction, stroke, body mass index).
Data generation and variant discovery. A total of 63.4 terabases of DNA sequence was generated at two centers with three complimentary definitions of the exome target and two different capture technologies (18). We sequenced samples from 14 different cohorts in the ESP to an average median depth of 111x (range 23x -474x). We found no evidence of cohortand/or phenotype specific effects, or other systematic biases, in the analysis of the filtered SNV data (18; Figs. S1-S7). Exomes from related individuals were excluded from further analysis (18; Fig. S8 ) resulting in a dataset of 2,440 exomes. We inferred genetic ancestry using a clustering approach (18), and focused the remaining analyses on the inferred 1,351 EA and 1,088 AA individuals. We subjected the 563,698 variants in the intersection of all three capture targets to standard quality control filters (18) resulting in a final data set of 503,481 single nucleotide variants (SNVs) identified in 15,585 genes and 22.38 Mb of targeted sequence per individual. We assessed data quality and error rates using complementary strategies (18). Approximately 98% (941/961) of all variant sites that were experimentally tested were confirmed, including 98% (234/238) of singletons, 98% (678/693) of nonsingleton SNV sites with a MAF < 10%, and 97% (29/30) of SNV sites with a MAF ≥ 10%.
The vast majority of coding variation is rare and novel. We observed a total of 503,481 SNVs and 117 fixed, non-reference sites, of which 325,843 and 268,903 were found in AA and EA, respectively (18; Fig. S9A ). Excluding singletons, ~58% of SNVs were populationspecific (93,278 and 32,552 variants were uniquely observed in AA, or EA, respectively), and the vast majority of these variants were rare (18; Fig. S9B ). Approximately 98% (402,813) of novel SNVs were rare, and 48.9% of all novel, rare SNVs were nonsynonymous.
The AA and EA sample sizes provided ~90% power to detect variants with a MAF ≥ 0.1%, and nearly 100% power to detect common variants (MAF ≥ 5%) (18; Tables S1, S2, Fig. S10 ). With our large sample size, the proportion of singletons identified rapidly decreased to a nearly constant rate of new singleton discovery such that each additional exome contributed ~200 novel SNVs (18; Fig. S11 ). The number of SNVs per gene rapidly stabilized for common variants in small sample sizes (~100 individuals), whereas the number of rare variants continued to increase linearly (18; Fig. S12 ). Of the total SNVs, 57% (285,857) were singletons, and SNVs with ≤ 3 minor alleles accounted for 72% of all variants (18; Fig. S9D ). The proportion of singletons observed in AA (49.3%, n=140,818) was lower than that observed in EA (50.7%, n=144,821), but the overall site frequency spectra (SFS) and the SFS for both AA and EA are highly skewed, exhibiting a large excess of rare variants relative to the standard neutral model (18, 19; Fig. S9D ). The skew of the SFS was greater for EA than AA and at equal sample sizes, the odds that a SNV was a singleton was 1.7 times greater for EA than AA. Consistent with these observations, Tajima's D was highly negative for both EA (-2.12) and AA (-2.10) and dropped precipitously as sample size increased (18; vides unique information about recent demographic history (13, 20, 21) .
To identify putatively functional variation, we applied four popular methods applicable to nonsynonymous variants (PolyPhen2, SIFT, a likelihood ratio test, and Mutation Taster) and three conservation based methods applicable to all types of variants (GERP, PhyloP, and a novel population genetics approach that combines conservation information with the SFS that we designate SFS-Del; (18). Approximately 47% of all SNVs (74% of nonsynonymous and 6% of synonymous variants) are predicted to be deleterious by one or more method (Fig. 1A) ; however overlap among methods is modest. For example, only 1% of nonsynonymous variants are predicted to be functional by all seven methods, and variants predicted by any single approach are likely to have a high false positive rate (Fig. 1A) . Therefore, we used a conservative majority rule approach and deemed nonsynonymous variants predicted by at least four of the seven applicable methods and synonymous sites predicted by at least two of the three applicable methods (Fig. S13) to be putatively functional. In total, 16.9% of SNVs (85,224) meet this criteria, of which 81,170 were nonsynonymous SNVs. Approximately 95.7% (81,555) of all SNVs conservatively predicted to be functional were rare, and the odds ratio that rare variants are functional compared to variants with a MAF > 0.5% is 4.2 (95% CI 4.0 -4.3; Fisher's exact test; p < 10 −15 ), underscoring the potential impact of rare variants on health-related traits.
Patterns of coding variation by gene and pathway. The median number of SNVs per gene was 24, ranged between 0 and 761, and was significantly different (Wilcoxon-Rank Sum Test; p-value < 10 −15 ) between AA (median 16, range 0-566) and EA (median 13, range 0-410). Mutational target size plays an important role in governing differences in polymorphism across loci, as gene length accounts for 76.6% of variation in the number of SNVs across genes (95% bootstrap CI = 73.9%-79.1%; p < 10 −15 ). The proportion of rare variants per base pair (bp) in each gene was higher (mean = 2.015%; 95% range = 0.621% -4.057%) than that of common variants (0.334%; 95% range = 0.000% -1.143%), and the average ratio of rare to common alleles per bp was ~6:1. We identified 110 genes that showed an unusually high proportion of rare variants, including six histone genes that are likely subject to greater selective constraint (18; Table S3 ). The number of putatively functional variants also varied widely across genes (Fig. S14B) ranging from 0 to >100, with a median of two in both the EA and AA samples Nucleotide diversity (π), varied considerably among genes, ranging from ~0 to 1.319% per bp (mean = 0.042%; Fig. 1B) . Mean π in AA (0.047%) was significantly higher (p-value < 10 −15 , paired t test) than π in EA (0.035%), and π per gene was modestly correlated (r 2 = 63%; pvalue < 10 −15 ) between AA and EA (18; Fig. S15 ). Rare variants account for 4% of total diversity, more than any other MAF bin (of width 0.5%) in both EA and AA (Fig. 1C) . Rare and low frequency SNVs comprise ~13% and 20% of total diversity in the EA and AA sample, respectively (Fig. 1C) . In both samples, estimates of π were highest for HLA loci and other genes related to immune function, such as DEFB108B, and olfactory receptors (Fig. 1B) . When genes were grouped into functional categories by KEGG pathway, estimates of π were highest for pathways related to immune function and olfaction and lowest for pathways involved in basic cellular processes (18; Fig. S16 ).
Abundance of rare variation explained by human demographic history. The excess of rare variation across the exome is consistent with explosive human population growth (22) . To investigate this further, we used an Out-of-Africa (OOA) demographic model (23) to predict the expected joint distribution of allele frequencies between the EA and AA samples via a diffusion approximation (18). The OOA model, modified to account for admixture, captures prominent features of the joint frequency distribution. However, both populations contain more rare variants than predicted by this model (18; Fig. 2A,B) , most likely due to rapid population growth in the last few thousand years that is undetectable with smaller sample sizes (18; Fig. S9E ). We revisited the demographic model from Gravel et al. (23) , allowing for a reduced initial European expansion that is compensated for by accelerated growth starting after the split of European and Asian populations. Similarly, we introduced a phase of exponential growth in the African population starting at the same time. The resulting demographic model is an improved fit to the synonymous site-frequency spectrum (18; Fig. 2B) , and strongly supports a recent, dramatic acceleration of population growth. The maximum-likelihood time for accelerated growth was 5,115 years ago (Fig. 2B) .
The EA population growth, previously estimated at 0.5% per generation, is now modeled at the first step as 0.307% (sd ± 0.003%), followed by explosive growth of 1.95% (sd ± 0.03%) over the last 5,115 years. The growth in the AA sample during this same period is estimated to be 1.66% (sd ± 0.03%). The estimated standard deviations (18) are quite small, and for data sets of this scale, it is likely that other sources of uncertainty (e.g., mutation rate or model specification) play a more important role compared to finite genome fluctuations. The final population sizes in this model are lower than current census sizes, and we speculate that larger sample sizes will be necessary to fully capture the signature recent growth rate expansion imparted on patterns of DNA sequence variation.
Impact of natural selection on rare coding variation. To investigate the effect of purifying selection on nonsynonymous variants, we examined the relationship between MAF of nonsynonymous SNVs and functional prediction scores from SIFT, Polyphen2, a likelihood ratio test statistic, and MutationTaster (18). Each prediction score showed a significant (p < 10 −16 ) negative correlation with MAF in the combined sample (Fig. 3A) as well as in each sample separately (18). Moreover, the proportion of predicted deleterious changes was negatively correlated with MAF (Fig. 3B) . We next mapped 31,115 nonsynonymous SNVs to known protein structures and classified them into different structural categories ( Fig. 3C; 18) . Nonsynonymous SNVs in all categories, except sites that contact other protein chains, showed a significant excess of rare variants compared with synonymous sites (Fig. 3C) , as expected if subjected to purifying selection. The relative effect sizes show that categories of variants with direct functional importance (e.g., active sites, enrichment 2.8%; ligand-binding residues, enrichment 1.7%) are under stronger constraint than categories important for structural stability. The exception is residues that form side-chain hydrogen bonds, which show a 2.8% enrichment of rare variants, suggesting that hydrogen bonds make To investigate selective constraint acting on synonymous variants, we calculated the correlation between the derived allele frequency (DAF) of synonymous variants and their corresponding change in the relative adaptiveness value, or w score (24) . The w score summarizes information about selective constraints on the efficiency of codonanticodon coupling and the number of tRNA gene copies in the genome. Negative values indicate synonymous variants that may decrease translational efficiency or accuracy. We found a weak but significant positive correlation between DAF and change in w score (r = 0.03; p-value < 10 −16 ), consistent with the action of purifying selection (Fig. 3D) . We examined selective sweeps by identifying genes with high ratios of divergence (human-specific lineage substitutions relative to chimp and macaque) compared to polymorphism within humans, which are predicted to increase between-species divergence and decrease withinpopulation diversity. We identified genes in which the ratio of nonsynonymous to synonymous divergence was high relative to the ratio of nonsynonymous to synonymous SNVs (25) . We also identified genes with either a high or low ratio of π in AA relative to π in EA and genes with diversity estimates in the bottom 20 th percentile in which at least one SNV had an F ST ≥ 0.3. In total, 114 genes met one or more of these criteria (18 ; Table S4 ). Approximately 25% of these genes have been implicated as targets of positive selection (26). The 114 candidate selection genes were significantly enriched (FDR ≤ 5%) for five KEGG pathways including olfactory transduction and metabolic pathways (18 ;  Table S5 ).
Implications for disease and personal genomics. We evaluated gene-specific power of rare variant association studies in the EA and AA samples. We used Fisher's Exact Test (FET), a robust approach for aggregate testing of rare variation at a locus (27) , to determine the power to detect an association for each gene harboring rare causal variants with 
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odds ratios (OR) of 1.5 or 5 in 400 cases and 400 controls (18). In both the EA and AA samples, cases and controls were sampled from 1,000 individuals selected to minimize any confounding effects of population stratification (18; Fig. S17 ), with power calculations assuming a Type I error rate of α=0.001. In each sample, power varies widely across loci, and <5% of genes achieve 80% power even when relatively strong effects (OR = 5) are modeled (Fig. 4A) ; when causal variants are assumed to have an OR of 1.5, no genes achieve 80% power (18; Fig. S18 ). Furthermore, although the AA sample has uniformly higher power per gene relative to the EA sample (Fig. 4A) , caution is warranted because this is largely a function of our modeling assumptions (18).
The mean number of SNVs per exome (homozygous non-reference and heterozygous genotypes) was 13,595, and ~66% (8, 893 ) of these sites were heterozygous. As expected, AAs had significantly more SNVs per exome than EAs (15,073 versus 12,406, Mann-Whitney test, p < 10 −16 ), which is true for all classes of sites (Fig. 4B) . Moreover, on average, each individual possessed 35 nonsense variants and was homozygous for at least one non-reference nonsense variant; 318 individuals (181 AA and 137 EA) were compound heterozygotes for nonsense SNVs. The mean number of novel SNVs per individual was 549 overall, but AA had more than twice the number of novel SNVs compared to EA's (762 versus 362, respectively; p = 1.9 × 10 −7 correcting for differences in the mean number of SNVs between populations). The fraction of overall variation that was novel in AA was higher than in EA (5% and 3%, respectively; p < 10 −16 ). Finally, while most protein coding variants were rare in the full AA and EA population samples, the majority of SNVs found in an average individual were common (Fig. 4C) .
We next examined the distribution of functionally important varia- (Fig. 4D ) using both conservative and liberal criteria (18). On average, individuals possess between 318 and 580 predicted functional protein-coding SNVs depending on how functional variants are defined, with slightly more in AA than in EA individuals (Fig. 4D) . The average number of predicted functional singletons per individual was more robust to the definition of functional variants, and ranged from 25 to 31, and also was slightly higher in AA compared to EA individuals (Fig. 4D) . In both cases, however, there was more variation among individuals than between populations.
Finally, the average proportion of predicted functional SNVs per individual varied between 2.3% and 4.2% (Fig. 4D) . When the more liberal definition of functional SNVs was used, EA individuals have a significantly higher proportion of predicted functional SNVs compared to AA individuals ( Fig. 4D ; Wilcoxon-Rank Sum Test; p-value < 10 −15 ), consistent with empirical estimates and theoretical expectations due to the lower EA effective population size (28, 29) . However, when the more conservative definition was used, this pattern was reversed and AA individuals have a significantly higher proportion of predicted functional SNVs compared to EA individuals ( Fig. 4D ; Wilcoxon-Rank Sum Test; p-value < 10 −15 ). These results highlight how the definition of functional variants can influence inferences and underscore the importance of continued methodological development to robustly identify functionally important variation. Nonetheless, there was considerable rare genetic variation among individuals that is predicted to be functional, which could explain variability in disease risk and adverse drug response.
Conclusion. Our results have several important implications for human disease gene mapping and personal genomics. In particular, the vast majority of protein-coding variation is evolutionarily recent, rare, and enriched for deleterious alleles. Thus, rare variation likely makes an important contribution to human phenotypic variation and disease susceptibility. However, detecting the effects of rare variants requires very large sample sizes because the power to detect an association is low for most human genes. Accounting for the SFS on a gene-by-gene basis should facilitate the development of more powerful association tests. Additionally, because most rare SNVs are population-specific, replication of disease associations across populations may be challenging. Finally, as whole-genome sequencing at high coverage becomes increasingly feasible, statistical and experimental methods that accurately identify functionally important protein-coding and regulatory variation are needed to empower association studies, identify variants causally related to disease, and provide clinically actionable information.
